|Bid||1.6900 x 1400|
|Ask||1.7100 x 900|
|Day's Range||1.6700 - 1.7300|
|52 Week Range||1.1650 - 6.9200|
|Beta (3Y Monthly)||5.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 11, 2019 - Nov 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.03|
OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company providing actionable answers at critical decision points across the cancer care continuum, today announced the company will present data highlighting its proprietary liquid biopsy test, which has the potential to determine which nodules are benign to reduce the number of unnecessary biopsies and associated complications, during the CHEST Annual Meeting 2019. OncoCyte is a molecular diagnostics company providing actionable answers at critical decision points across the lung cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The company is currently developing a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence, allowing them to be treated when their cancer is still responsive to adjuvant chemotherapy.
OncoCyte Corporation (“OncoCyte”) (NYSE American: OCX), a developer of novel tests for the early diagnosis and management of lung cancer, today announced that it has closed its previously announced initial investment in a 25% preferred stock interest in Razor Genomics, Inc. (“Razor”) and has acquired rights to commercialize Razor’s CLIA-validated lung cancer treatment stratification test. The Razor test enables the identification of early-stage lung cancer patients at high risk for recurrence and allows them to be treated at a time when their cancer can still be responsive to adjuvant chemotherapy.
OncoCyte Corporation (NYSE American: OCX), a developer of novel tests for the early diagnosis and management of lung cancer, today announced that it has entered into a definitive agreement to acquire Razor Genomics. An initial closing at which OncoCyte will acquire shares of Razor preferred stock representing 25% of the outstanding equity of Razor, is expected to close by the end of September, subject to customary and other closing conditions. OncoCyte will have the option to acquire the balance of the outstanding shares of Razor common stock from Razor’s shareholders (the “Purchase Option”).
Molecular Diagnostics industry veteran Ron A. Andrews appointed CEO Melinda Griffith elected to Board of Directors Strengthened Clinical Operations and Commercial Marketing.
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the second quarter ended June 30, 2019, on Wednesday, August 14, 2019, after the close of the U.S. financial markets. The Company will host a conference call on Wednesday, August 14, 2019, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments. To access the live webcast, go to the investor relations section on the Company’s website, http://public.viavid.com/index.php?id=135362.
NEW YORK , July 26, 2019 /PRNewswire/ -- Acer Therapeutics Inc. (ACER) Lifshitz & Miller announces investigation into possible securities laws violations in connection with a CRL for EDSIVO. If you are ...
OncoCyte Corporation (NYSE American: OCX), a developer of novel, molecular diagnostic tests for the early detection and management of cancer, today announced the appointment of Melinda Griffith to its Board of Directors. “We are delighted to have Melinda, an accomplished life sciences industry executive, join our board during this exciting time of growth for OncoCyte,” said Ronald Andrews, President and Chief Executive Officer. Ms. Griffith is a senior executive with extensive experience leading the business development, licensing and legal activities of diagnostic, device and pharmaceutical companies.
NEW YORK, NY / ACCESSWIRE / July 11, 2019 / Pomerantz LLP is investigating claims on behalf of investors of OncoCyte Corporation (“OncoCyte” or the “Company”) (NYSEAMERICAN: OCX). Such investors are advised ...
NEW YORK, NY / ACCESSWIRE / July 2, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of OncoCyte Corporation ("OncoCyte" or the "Company") ...
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today provided a mid-year update and announced that the Company will require additional time to complete its ongoing CLIA Validation study of DetermaVu™, its liquid biopsy test for lung cancer. In the CLIA Validation Study, started in late April, OncoCyte is assaying approximately 120 samples previously tested in its R&D Validation study, with the goal of demonstrating that the same results can be obtained in the Company’s CLIA-validated laboratory.
OncoCyte Corporation (NYSE: OCX ) is set to join the Russell 2000, Russell 3000 and Russell Microcap Indexes July 1. The Russell 3000 Index is a capitalization-weighted stock market index maintained by ...
OncoCyte Corp NYSE MKT:OCXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for OCX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting OCX. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding OCX are favorable, with net inflows of $521 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that the company will be added to the Russell 2000®, Russell 3000® and Russell Microcap Indexes, effective when the U.S. markets open on July 1, 2019. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000® Index. “We are pleased to be joining these three Russell indexes,” commented William Annett, President and CEO of OncoCyte.
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that diagnostics industry veteran and current Board member Ronald Andrews will assume the role of Chief Executive Officer, effective July 1. Mr. Andrews brings to OncoCyte over 30 years of diverse experience in the clinical and molecular diagnostics field, with a particular focus on oncology.
ALAMEDA, Calif., May 29, 2019 -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that.
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced the appointment of Padma Sundar, an industry leader in oncology diagnostics strategy and marketing, as Senior Vice President of Marketing and Market Access, effective May 22, 2019. The Company also announced the appointment of Dr. Kim Dickinson, a recognized leader in clinical operations and pathology, as Vice President of Clinical Operations, effective May 28, 2019.
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today presented results from the Company’s R&D Validation study at the American Thoracic Society (ATS) 2019 International Conference, which is being held May 17 to May 22 in Dallas. The poster details the compelling results from the Company’s successful R&D Validation study of DetermaVu™, OncoCyte’s liquid biopsy test for the early detection of lung cancer.